In The News

Scientists Make Critical End-Stage Liver Disease Discovery

Scientists At The UA Make Critical End-Stage Liver Disease Discovery April 28, 2014 The discovery of an unknown cellular pathway has helped scientists and physicians better understand end-stage liver disease and offers a potential target for new therapeutics A team of researchers in the University of Arizona’s College of Pharmacy has discovered a molecular pathway…

Read More

The cure for hepatitis C is upon us

The cure for hepatitis C is upon us, but at a costly penny ANDRÉ PICARD (Corrected version) The Globe and Mail Published Sunday, Apr. 27 2014, 4:00 PM EDT Last updated Sunday, Apr. 27 2014, 10:33 PM EDT There is a revolution coming to the treatment of hepatitis C. But a big fat asterisk is…

Read More

New Liver Drug Big News for Intercept

New Liver Drug Big News for Intercept Intercept Pharmaceuticals, Inc reported big news, that its new liver drug, obeticolic acid (OCA), can effectively treat primary biliary cirrhosis (PBC), an autoimmune disease that damages bile ducts in the liver. The findings bring the company a step closer to filing for market approval. Intercept is unique for…

Read More

Living With Auto-Immune Heptatitis

Living With Auto-Immune Heptatitis Comments (0) Out of the blue, Marina Barlow developed a yellow hue to her skin – jaundice – and found herself in the Bristol Royal Infirmary for a week where doctors diagnosed auto-immune hepatitis, for which there is no cure. So Marina, who is 29 and lives in Filton, is stuck with…

Read More

Regulation of Vitamins: Politics As Usual

Regulation of Vitamins: Politics As Usual Commentary by Rolf Hefti (OMNS Jan 7, 2014) Medical politics has been pervaded with unfounded, misleading arguments, tantamount to propaganda, instead of good evidence. Over the last several decades, the US mainstream medical establishment and the public health authorities, along with the help of the medical industry-sponsored mass media,…

Read More

FDA approves OLYSIO (simeprevir) for treatment of chronic hepatitis C infection

FDA approves OLYSIO (simeprevir)  Janssen Therapeutics, Division of Janssen Products, LP (Janssen), announced today the U.S. Food and Drug Administration (FDA) has approved OLYSIO™ (simeprevir), an NS3/4A protease inhibitor, for the treatment of chronic hepatitis C infection as part of an antiviral treatment regimen in combination with pegylated interferon and ribavirin in genotype 1 infected…

Read More

FDA approves new treatment for hepatitis C virus

FDA approves new treatment for hepatitis C virus FDA NEWS RELEASE For Immediate Release: Nov. 22, 2013 Media Inquiries: Stephanie Yao, 301-796-0394, stephanie.yao@fda.hhs.gov Consumer Inquiries: 888-INFO-FDA FDA approves new treatment for hepatitis C virus The U.S. Food and Drug Administration today approved Olysio (simeprevir), a new therapy to treat chronic hepatitis C virus infection. Hepatitis…

Read More